Statin Therapy for Prevention of Anthracycline Cardiotoxicity - Another Defeat for Cardioprotection?
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 38319795.
- Also identified by DOI 10.1056/EVIDe2200166.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Reduction in left ventricular (LV) systolic function and clinical heart failure (HF) are well-known potential consequences of anthracycline therapy for cancer. Putative mechanisms include myocardial dysfunction and damage caused by the production of reactive oxygen species and topoisomerase II-mediated cell death.<sup>1,2</sup> Interest in the use of statins as a preventive strategy against anthracycline-mediated cardiotoxicity centers on the pleotropic (anti-inflammatory) effects of statin therapy.<sup>3</sup> Support for statins as potential cardioprotective agents during anthracycline-based chemotherapy stems from observational cohort studies, two small prospective trials, and meta-analyses.
Medical subject headings
- Anthracyclines
- Hydroxymethylglutaryl-CoA Reductase Inhibitors